-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
New DOJ Case Shows Cross-Silo Accuracy a Key Function of Compliance
Sep 18, 2019
An announcement from the Department of Justice should put all Life Sciences companies on notice. The United States Attorney’s Office for the Southern District of New York recently filed a civil healthcare fraud lawsuit with significant implications: Regulators are actively examining the data manufacturers submit to comply with the Sunshine Act and comparing it with companies’ own internal data. When discrepancies arise, the legal ramifications can be severe.
Manufacturers should consider this a cautionary tale: Those which find themselves embroiled in an investigation must prioritize a new imperative in addition to the completeness and accuracy of their own internal data; namely, manufacturers need to make sure they have cross-silo systems in place to ensure accuracy and mitigate errors both internally and externally.
The allegations in the government’s case against Life Spine, Inc. along with two of its key executives, pertain to compensation surrounding HCP relationships. The false claims complaint alleges that kickbacks were paid to hospitals and surgeons in the form of payments such as consulting fees, royalties, and intellectual property acquisition fees. This, in turn, triggered false claims submissions to Medicare and Medicaid, the DOJ alleges. Those fees were often codified into training, education and product development agreements, but the Justice Department’s complaint alleges that these payments were in fact tied to the surgeons’ frequent and continual use of the company’s products. The complaint alleges that internal Life Spine documents show that the company tracked the volume of sales generated by these surgeons with which Life Spine had relationships and that both parties were in acknowledgment of the expectations.
These payments totaled more than $7 million over a time frame of roughly seven years, payments that were not appropriately documented according to regulations stipulated by the Centers for Medicare and Medicaid Services Physician Payment Sunshine Act. The complaint also noted that the surgeons recruited by the company were responsible for roughly half of the company’s domestic sales for the time period under investigation.
The complaint, and the language in it, make it clear that regulatory and law enforcement bodies are evaluating the material submitted by companies to the federal Open Payments data platform and will not hesitate to take action if they uncover discrepancies — and the industry should expect that this would hold true for even inadvertent mistakes.
The stakes here are high: This case should serve as a reminder to all Life Sciences companies that merely documenting and reporting HCP compensation in the context of promotional education, speaker programs and consultative relationships is not enough. The onus is on the industry to be proactive: Manufacturers of drugs and medical devices need to establish comprehensive, compliance-centric systems for monitoring and reporting. Error mitigation and, when necessary, rectification needs to be a top goal.
The increasing scrutiny of the Life Sciences industry and regulatory zeal for investigating perceived infractions means that companies without such managerial infrastructure are exposed to the risk of legal scrutiny and even prosecution. Due diligence in cross-referencing reporting results needs to be integrated at the most fundamental level of all HCP management platforms.